The future of folic acid antagonist therapy in rheumatoid arthritis
β Scribed by Christoph Fiehn
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 49 KB
- Volume
- 60
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## Objective To determine if folinic acid supplementation during methotrexate (MTX) therapy for rheumatoid arthritis (RA) reduces both urinary 5βaminoimidazoleβ4βcarboxamide (AICA) and urinary adenosine excretion more than does folic acid supplementation. AICA and adenosine are markers
Twenty-three rheumatoid arthritis patients who had previously received gold therapy were selected for second course gold. Eleven patients had developed complete remission during the first course of gold therapy. Four of these had a complete response to second course gold. Of the 10 nonresponders and